NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
30.41
-2.42 (-7.39%)
At close: Mar 3, 2026, 4:00 PM EST
30.45
+0.04 (0.15%)
Pre-market: Mar 4, 2026, 4:28 AM EST
NAMS Revenue
In the year 2025, NewAmsterdam Pharma Company had annual revenue of $22.50M, down -50.61%. NewAmsterdam Pharma Company had revenue of $32.00K in the quarter ending December 31, 2025, a decrease of -99.75%.
Revenue (ttm)
$22.50M
Revenue Growth
-50.61%
P/S Ratio
155.35
Revenue / Employee
$225,030
Employees
100
Market Cap
3.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.50M | -23.06M | -50.61% |
| Dec 31, 2024 | 45.56M | 31.47M | 223.37% |
| Dec 31, 2023 | 14.09M | -88.60M | -86.28% |
| Dec 31, 2022 | 102.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Legend Biotech | 909.05M |
| Corcept Therapeutics | 761.41M |
| ADMA Biologics | 510.17M |
| Ligand Pharmaceuticals | 268.09M |
| Centessa Pharmaceuticals | 15.00M |
| Crinetics Pharmaceuticals | 7.70M |
| Xenon Pharmaceuticals | 7.50M |
NAMS News
- 6 days ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - GlobeNewsWire
- 13 days ago - NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 25 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 7 weeks ago - NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December - GlobeNewsWire
- 3 months ago - NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating - Seeking Alpha